Elanco Animal Health Incorporated (ELAN)
$
20.22
+0.18 (0.89%)
Key metrics
Financial statements
Free cash flow per share
0.7149
Market cap
9.8 Billion
Price to sales ratio
2.1893
Debt to equity
0.6213
Current ratio
2.5963
Income quality
1.3180
Average inventory
1.6 Billion
ROE
0.0674
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Elanco Animal Health Incorporated is an established player in the animal health sector, innovating and developing a diverse array of products designed for both pets and farm animals. The company reported an income before tax of 488,000,000.00 showcasing its pre-tax profitability. The cost of revenue for the company is $2,530,000,000.00 showcasing its production and operational expenses, while the total costs and expenses for the company are $4,188,000,000.00 reflecting its overall spending. Additionally, Elanco reported selling, general, and administrative expenses of $1,314,000,000.00 indicating its operational overhead costs. The weighted average number of diluted shares outstanding is 497,300,000.00 reflecting potential dilution effects. Elanco focuses on pet health with disease prevention products such as parasiticides and vaccines protecting pets from common parasites like worms, fleas, and ticks under renowned brands including Seresto, Advantage, Advantix, and Advocate. It also offers therapeutics for various conditions in canines and felines under the Galliprant and Claro brands. Moreover, the company provides vaccines, antibiotics, and nutritional health products for poultry and aquaculture, alongside essential products for ruminant and swine production under the Rumensin and Baytril brands. Elanco serves a broad customer base, including third-party distributors, veterinarians, and farm animal producers ranging from beef and dairy farmers to those in the pork and poultry sectors. As an organization, Elanco Animal Health operates within the Healthcare sector, driving innovation and growth within the industry. It is a key player in the Drug Manufacturers - Specialty & Generic industry, contributing significantly to the overall market landscape. Investors seeking budget-friendly options may find the stock affordable at $19.20 making it suitable for those who are budget-conscious. Additionally, the stock has a high average trading volume of 7,163,221.00 indicating strong liquidity in the market. With a mid-range market capitalization of $10,045,573,054.00 the company is recognized as a steady performer, showcasing its reliability and consistent contributions to the animal health field.
Is Elanco Animal Health Incorporated (ELAN) a good investment?
Investing in Elanco Animal Health Incorporated (ELAN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.
What is Elanco Animal Health Incorporated (ELAN)'s stock forecast?
Analysts predict Elanco Animal Health Incorporated stock to fluctuate between $8.02 (low) and $21.76 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Elanco Animal Health Incorporated's market capitalization?
As of 2025-10-14, Elanco Animal Health Incorporated's market cap is $10,045,573,054, based on 496,813,702 outstanding shares.
How does Elanco Animal Health Incorporated compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Elanco Animal Health Incorporated has a Lower Market-Cap, indicating a difference in performance.
How can I buy Elanco Animal Health Incorporated (ELAN) stock?
To buy Elanco Animal Health Incorporated (ELAN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ELAN. Place an order (Market, Limit, etc.).
What is the best time to invest in Elanco Animal Health Incorporated?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Elanco Animal Health Incorporated perform in the last earnings report?
Revenue: $4,439,000,000 | EPS: $0.68 | Growth: -127.20%.
Where can I find Elanco Animal Health Incorporated's investor relations reports?
Visit https://www.elanco.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Elanco Animal Health Incorporated?
You can explore historical data from here
What is the all-time high and low for Elanco Animal Health Incorporated stock?
All-time high: $36.50 (2021-08-05) | All-time low: $7.88 (2023-05-31).
What are the key trends affecting Elanco Animal Health Incorporated stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Does Elanco Animal Health Incorporated (ELAN) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Elanco Animal Health Incorporated (ELAN) or U.S. Physical Therapy (USPH). But which of these two companies is the best option for those looking for undervalued stocks?
zacks.com
Elanco Animal Health (ELAN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
prnewswire.com
FDA now concludes "t he totality of evidence supports removal of the risk of fatal vaccine-induced disease from modified live virus vaccines from the labeling"i Further evaluation of supplemental scientific data drove this FDA update; data now peer-reviewed and published Real-world success and experiences from dermatologists and general practice veterinarians around the U.S. and the world further demonstrate Zenrelia's efficacy INDIANAPOLIS , Sept. 23, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced important updates to the U.S. Zenrelia label, following the Food and Drug Administration (FDA) review of supplemental scientific data.
seekingalpha.com
Elanco Animal Health Incorporated (NYSE:ELAN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Jeffrey Simmons - President, CEO & Director Robert VanHimbergen - Executive VP & CFO Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Presentation Erin Wilson Wright Equity Analyst Hi. Good morning, everyone.
prnewswire.com
Credelio Quattro marked $100 million in net sales making it Elanco's fastest pet health blockbuster in history and one of the industry's fastest ever, especially with a single geographic approval Credelio Quattro joins Experior® as Elanco's second of six recently launched blockbuster-potential products to reach the $100 million annual net sales milestone Zenrelia™ (ilunocitinib tablets) now in market in the European Union (EU) and Great Britain GREENFIELD, Ind. , Sept. 8, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) has announced significant advancements with its two most recent pet health innovations—Credelio Quattro and Zenrelia—further demonstrating the company's commitment to helping pet owners and veterinarians around the world go beyond today's standard of treatment.
seekingalpha.com
Elanco Animal Health Incorporated (NYSE:ELAN ) Q2 2025 Earnings Conference Call August 7, 2025 9:00 AM ET Company Participants Jeffrey N. Simmons - President, CEO & Director Robert M.
seekingalpha.com
I rate Elanco Animal Health Incorporated shares a Buy with a $20 fair value, driven by strong innovation and recent operational improvements. Elanco's focus on innovative products like Zenrelia and strategic divestitures positions it for growth in both companion and farm animal markets. Strong Q2 results, raised full-year guidance, and increased innovation revenue targets support my positive outlook for future growth.
benzinga.com
Elanco Animal Health Incorporated ELAN reported second-quarter 2025 results on Thursday, posting adjusted earnings per share of 26 cents, down 13% year over year.
zacks.com
Although the revenue and EPS for Elanco Animal Health (ELAN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
See all news
